share_log

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Anderson J. Kermit

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities

Adial Pharmaceuticals | 4:持股变动声明
美股SEC公告 ·  2024/03/28 06:10

Moomoo AI 已提取核心信息

Adial Pharmaceuticals, Inc. (ADIL) has reported a transaction involving Anderson J. Kermit, a reporting person associated with the company. The transaction took place on March 25, 2024. However, the details regarding the nature of the transaction, such as the number of shares traded, the transaction price, and the resulting ownership stake, have not been disclosed. Investors are advised to await further information to fully assess the impact of this event on their investment decisions.
Adial Pharmaceuticals, Inc. (ADIL) has reported a transaction involving Anderson J. Kermit, a reporting person associated with the company. The transaction took place on March 25, 2024. However, the details regarding the nature of the transaction, such as the number of shares traded, the transaction price, and the resulting ownership stake, have not been disclosed. Investors are advised to await further information to fully assess the impact of this event on their investment decisions.
Adial Pharmicals, Inc.(ADIL)报告了一笔涉及与该公司有关联的举报人安德森·柯米特的交易。该交易于 2024 年 3 月 25 日进行。但是,有关交易性质的细节,例如交易的股票数量、交易价格以及由此产生的所有权,尚未披露。建议投资者等待进一步的信息,以全面评估该事件对其投资决策的影响。
Adial Pharmicals, Inc.(ADIL)报告了一笔涉及与该公司有关联的举报人安德森·柯米特的交易。该交易于 2024 年 3 月 25 日进行。但是,有关交易性质的细节,例如交易的股票数量、交易价格以及由此产生的所有权,尚未披露。建议投资者等待进一步的信息,以全面评估该事件对其投资决策的影响。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息